Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$11.02
At close: Jul 16 EDT
$11.00
-0.02-0.18%
Pre-Market: 4:04 PM EDT
Comments
Loading...
Verve Therapeutics Analyst Ratings and Price Targets | NASDAQ:VERV | Benzinga
Verve Therapeutics Inc has a consensus price target of $18.6 based on the ratings of 14 analysts. The high is $40 issued by Stifel on April 3, 2024. The low is $11 issued by Jefferies on June 18, 2025. The 3 most-recent analyst ratings were released by BMO Capital, HC Wainwright & Co., and LifeSci Capital on June 27, 2025, June 18, 2025, and June 18, 2025, respectively. With an average price target of $13 between BMO Capital, HC Wainwright & Co., and LifeSci Capital, there's an implied 18.18% upside for Verve Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
BMO Capital
HC Wainwright & Co.
LifeSci Capital
Jefferies
Canaccord Genuity
1calculated from analyst ratings
Analyst Ratings for Verve Therapeutics
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
06/27/2025 | 22.73% | BMO Capital | $20 → $13.5 | Downgrade | Outperform → Market Perform | |||
06/18/2025 | 22.73% | HC Wainwright & Co. | $13.5 → $13.5 | Downgrade | Buy → Neutral | |||
06/18/2025 | 9.09% | LifeSci Capital | → $12 | Downgrade | Outperform → Market Perform | |||
06/18/2025 | — | Jefferies | $28 → $11 | Downgrade | Buy → Hold | |||
06/17/2025 | — | William Blair | — | Downgrade | Outperform → Market Perform | |||
06/17/2025 | 18.18% | Canaccord Genuity | $39 → $13 | Downgrade | Buy → Hold | |||
04/15/2025 | — | William Blair | — | Reiterates | Outperform → Outperform | |||
04/15/2025 | — | Cantor Fitzgerald | — | Upgrade | Neutral → Overweight | |||
04/15/2025 | 118.18% | Guggenheim | $18 → $24 | Maintains | Buy | |||
04/15/2025 | 254.55% | Canaccord Genuity | $32 → $39 | Maintains | Buy | |||
04/14/2025 | 127.27% | HC Wainwright & Co. | $15 → $25 | Maintains | Buy | |||
03/25/2025 | — | Guggenheim | — | Reiterates | Buy → Buy | |||
03/25/2025 | 36.36% | HC Wainwright & Co. | $15 → $15 | Reiterates | Buy → Buy | |||
03/04/2025 | 36.36% | RBC Capital | $17 → $15 | Maintains | Outperform | |||
02/28/2025 | 36.36% | HC Wainwright & Co. | $14 → $15 | Maintains | Buy | |||
11/06/2024 | 190.91% | Canaccord Genuity | $29 → $32 | Maintains | Buy | |||
11/06/2024 | 54.55% | RBC Capital | $20 → $17 | Maintains | Outperform | |||
11/06/2024 | 27.27% | HC Wainwright & Co. | $15 → $14 | Maintains | Buy | |||
08/12/2024 | 163.64% | Canaccord Genuity | $30 → $29 | Maintains | Buy | |||
08/12/2024 | 36.36% | HC Wainwright & Co. | $15 → $15 | Reiterates | Buy → Buy | |||
08/09/2024 | 81.82% | RBC Capital | $25 → $20 | Maintains | Outperform | |||
05/09/2024 | 36.36% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy | |||
04/03/2024 | 263.64% | Stifel | $56 → $40 | Maintains | Buy | |||
02/28/2024 | 218.18% | RBC Capital | $35 → $35 | Reiterates | Outperform → Outperform | |||
09/13/2023 | 100% | Cantor Fitzgerald | → $22 | Reiterates | Neutral → Neutral | |||
08/29/2023 | 100% | Cantor Fitzgerald | → $22 | Reiterates | Neutral → Neutral | |||
08/15/2023 | 400% | Guggenheim | $56 → $55 | Maintains | Buy | |||
08/11/2023 | 181.82% | Credit Suisse | → $31 | Reiterates | Neutral → Neutral | |||
06/16/2023 | 163.64% | Canaccord Genuity | → $29 | Reiterates | Buy → Buy | |||
05/16/2023 | 218.18% | RBC Capital | → $35 | Reiterates | Outperform → Outperform | |||
04/13/2023 | 163.64% | Canaccord Genuity | → $29 | Initiates | → Buy | |||
02/01/2023 | 90.91% | Cantor Fitzgerald | → $21 | Initiates | → Neutral | |||
12/15/2022 | 18.18% | Goldman Sachs | → $13 | Initiates | → Sell | |||
11/08/2022 | 218.18% | RBC Capital | $42 → $35 | Maintains | Outperform | |||
10/06/2022 | 336.36% | Credit Suisse | → $48 | Initiates | → Neutral | |||
08/25/2022 | 409.09% | Stifel | $32 → $56 | Upgrade | Hold → Buy | |||
07/18/2022 | 463.64% | BMO Capital | $48 → $62 | Maintains | Outperform |
FAQ
What is the target price for Verve Therapeutics (VERV) stock?
The latest price target for Verve Therapeutics (NASDAQ:VERV) was reported by BMO Capital on June 27, 2025. The analyst firm set a price target for $13.50 expecting VERV to rise to within 12 months (a possible 22.73% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Verve Therapeutics (VERV)?
The latest analyst rating for Verve Therapeutics (NASDAQ:VERV) was provided by BMO Capital, and Verve Therapeutics downgraded their market perform rating.
When was the last upgrade for Verve Therapeutics (VERV)?
The last upgrade for Verve Therapeutics Inc happened on April 15, 2025 when Cantor Fitzgerald raised their price target to N/A. Cantor Fitzgerald previously had a neutral for Verve Therapeutics Inc.
When was the last downgrade for Verve Therapeutics (VERV)?
The last downgrade for Verve Therapeutics Inc happened on June 27, 2025 when BMO Capital changed their price target from $20 to $13.5 for Verve Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Verve Therapeutics (VERV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verve Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verve Therapeutics was filed on June 27, 2025 so you should expect the next rating to be made available sometime around June 27, 2026.
Is the Analyst Rating Verve Therapeutics (VERV) correct?
While ratings are subjective and will change, the latest Verve Therapeutics (VERV) rating was a downgraded with a price target of $20.00 to $13.50. The current price Verve Therapeutics (VERV) is trading at is $11.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
